Go to deals
Private Equity | Healthcare

Cooper Consumer Health has sold Stardea to EA Pharma

Cooper Consumer Health has sold Stardea to EA Pharma.

Founded in 2005 and based in Italy, Stardea is a recognized player in the fields of nutraceuticals, medical devices and dermocosmetics. The company has 56 products characterized by quality, effectiveness and safety, including 47 complex food supplements. Stardea’s products are structured around nine functional areas: cardiovascular, neurological, breathing, metabolic, musculoskeletal, gastroenterology, urological, pediatric and dermatological. The company distributes its products to pharmacies through medical referrals, with a network of doctors covering a large part of the country and a team of medical representatives to promote its products.

With a history of more than 70 years, the EA Pharma group is a pharmaceutical laboratory and a major player in Europe in the field of natural health and nutrition products. EA Pharma is the pioneer and undisputed leader in oligotherapy and a major European producer of food supplements marketed under its umbrella brands Granions and Eafit in France and Drasanvi in Spain. The group also sells sports and health nutrition products and natural cosmetics.

Cooper Consumer Health is a leading independent European pure play self-care platform with more than 90% of its sales coming from OTC products and covering more than 30 OTC segments. Today, more than 80,000 pharmacists advise Cooper Consumer Health's self-care solutions.

Oaklins’ team in France supported Cooper Consumer Health on the sale of Stardea to EA Pharma. The team in Italy supported the transaction by facilitating the communication between the parties.

Parties

Talk to the deal team

Antoine Lemaire

Partner
Paris, France
Oaklins France

Giuseppe Maria Bernardo Puccio

Principal
Milan, Italy
Oaklins Italy

Charlotte Delphis

Associate Director
Paris, France
Oaklins France

Related deals

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more
Armira has signed an agreement to acquire a majority stake in Viabus
Private Equity | Consumer & Retail

Armira has signed an agreement to acquire a majority stake in Viabus

Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.

Learn more
Triscan has joined APA and Riverarch to accelerate growth in the European aftermarket
Private Equity | Automotive

Triscan has joined APA and Riverarch to accelerate growth in the European aftermarket

Triscan AS, a leading provider of OE-quality automotive spare parts for the professional aftermarket in Europe, has been acquired by APA Industries, LLC, a portfolio company of Riverarch Equity Partners.

Learn more